sorafenib,bevacizumab,atezolizumab,lenvatinib
eisai,roche,bayer
[]
#lenvatinib following progression on immunotherapy may have survival benefit for patients with advanced hepatocellular carcinoma, according to findings presented at #gi23. #gicsm #hcc | 
Oncology news and insights from leading researchers and cancer centers.